Christopher Dean

Establishing a National SABR Service: A Model for Safe and Effective Clinical Implementation

Patricia Díez, R. Patel, Anoop Haridass, Matthias Kroiß et autres

gb (code pays fourni par la source)

STAG2 mutations in the normal colon induce upregulation of oncogenic pathways in neighbouring wildtype cells

Wei Ni Yew, Christopher Dean, Dedrick Kok Hong Chan

sg (code pays fourni par la source)

BRAINSTEM METASTASES TREATED WITH STEREOTACTIC RADIOSURGERY AT BARTS HEALTH NHS TRUST: FEASIBILITY, TOLERABILITY AND EffiCACY

bhavna oza, Sweta Bowles, Christopher Dean, Rachel Lewis et autres

gb (code pays fourni par la source)

1958 SRS for patients with benign disease: can extracranial dose be reduced whilst maintaining acceptable plan quality with multi-arc non-coplanar VMAT?

David Eaton, Christopher Dean

EGS SO11 - A Retrospective Review of Perioperative Outcomes after Laparoscopic Cholecystectomy in Older Patients

Hermione Jemmett, Emily Khoo, Christopher Dean, Hariprasath Kanesan

gb (code pays fourni par la source)

ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia

Clifford M. Csizmar, Mark E. Gurney, Rashmi Kanagal‐Shamanna, Kelly S. Chien et autres

us (code pays fourni par la source)

PTPN11variants in chronic myelomonocytic leukemia: Phenotypic and prognostic correlates.

Anuya Ajit Natu, Clifford M. Csizmar, Mark E. Gurney, Terra L. Lasho et autres

us (code pays fourni par la source)

941: Should Varian HyperArc make us re-think how we use conventional linacs for SRS?

Christopher Dean, Sweta Bowles, Niall MacDougall, Hamoun Rozati et autres

2778: Establishing intrafractional patient positional uncertainty for Varian HyperArc: a novel approach

Joseph Dallman, Christopher Dean

Cellular Interactions within Clonal Dendritic Cell Aggregates Drive Immune Tolerance in Chronic Myelomonocytic Leukemia Bone Marrow Microenvironment

Abhishek A. Mangaonkar, Terra L. Lasho, Justin C. Boysen, Christy M. Finke et autres

us (code pays fourni par la source)

ASXL1/ TET2 Genotype-Based Risk Stratification Outperforms ASXL1 Mutational Impact and Is Independent of Mutant Variant Allele Fractions (VAF) in CMML

Clifford M. Csizmar, Mark E. Gurney, Rashmi Kanagal‐Shamanna, Kelly S. Chien et autres

us (code pays fourni par la source)

External beam treatment planning

Christopher Dean, Niall MacDougall, Andrew Morgan